Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

NCT02614833 is registered in ClinicalTrials.gov with Immutep S.A.S. as lead sponsor.

NCT NCT02614833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02614833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Lead sponsor
Immutep S.A.S.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
May 31, 2021
Enrollment
242 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma breast stage iv